FIELD: medicine, pharmaceutics.
SUBSTANCE: invention represents new derivatives of cyclopamine having the following formula. 
wherein R1 -H, alkyl, -OR, amino, sulphonamido, sulphamido, OC(O)R5, -N(R5)C(O) R5, R2 - H, heterocycloalkyl, or R1 and R2 together form =O, =S, =N(OR), N(NR2) or =C(R)2, R3 - H, R4 -H, alkyl, OR5, -C(O)R5, [(W)-C(O)O]qR5, -W-NR5 3X- etc., wherein W is an alkyl diradical, X halogenide, R5 - H, alkyl, alkenyl, aryl, cycloalkyl, etc.
EFFECT: compounds possess inhibitory action on the tumour growth.
38 cl, 27 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR USING CYCLOPAMINE ANALOGUES | 2007 |
|
RU2492859C2 |
| IAP INHIBITORS | 2008 |
|
RU2491276C2 |
| CYCLOPAMINE ANALOGUES AND METHODS OF THEIR APPLICATION | 2005 |
|
RU2403256C2 |
| C40-, C28- AND C-32-LINKED RAPAMYCIN ANALOGUES AS MTOR INHIBITORS | 2019 |
|
RU2805211C2 |
| PYRIMIDINES AND THEIR OPTIONS, AND THEIR APPLICATION | 2017 |
|
RU2760733C2 |
| ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2824528C2 |
| PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2014 |
|
RU2677653C2 |
| COMPOUNDS AND METHODS OF INHIBITING INTERACTION OF BCL PROTEINS WITH BINDING COMPONENTS | 2005 |
|
RU2416606C2 |
| TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
| CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | 2016 |
|
RU2732405C2 |
